Cell Signaling Technology, Inc.

10/19/2026

🧬🫸 Where will next-generation inhibitors, targeted protein degradation (TPD), and combo therapies take the study of cell proliferation? Completely halting proliferative signaling is challenging due to pathway redundancy, resistance, and rewiring. Discover how recent advances in drug design are overcoming this challenge to create more effective, targeted cancer treatments. Learn more about the Cancer Hallmark: Sustaining Proliferative Signaling on the .

A Hallmark of Cancer, sustaining proliferative signaling is used by cancer cells to stimulate growth and relies on Akt, MAPK/Erk, and MTOR pathways.

10/16/2026

The genetic cause of Huntington’s disease is known—but its downstream biology remains complex. Explore key HD biomarkers, from mHTT and NfL to DARPP-32 and YKL-40, along with validated CST antibody tools for studying them.

Explore key Huntington's disease biomarkers and validated CST antibodies for studying mHTT, neuronal loss, striatal dysfunction, and neuroinflammation.

10/16/2026

💀 Resisting cell death is a textbook hallmark of cancer—but do you know how your model is really doing it?

👉 From caspases and Bcl‑2 family members to IAPs and BH3‑only “gatekeepers,” see which signaling nodes tumors hijack to resist apoptosis and survive cellular stress and damage on the .

Discover how cancer cells evade apoptosis and other death pathways and explore key targets, markers and tools to study the Hallmark of Resisting Cell Death

10/14/2026

Discover how CST chimeric monoclonal antibodies enable low-plex, multi-species imaging of key brain cell markers with greater panel flexibility.

Poster Presentation Details:
📆 Day: 14-15 October
⏰ Time: 13:30 - 14:00
🖼️ Poster #: 238

Stop by our poster at ELRIG Drug Discovery 2026 to chat with our team, or visit our booth to learn more!

10/12/2026

🧬🔬Trying to identify the epigenetic reprogramming mechanism responsible for the change in gene expression? Analyze epigenetic regulator proteins via chromatin profiling to identify changes in epigenetic signatures across the genome.

👉 Explore key DNA methylation and histone modification targets plus CST antibodies and chromatin profiling kits on the .

Learn how cancer epigenetics uses DNA methylation and histone modification to fuel nonmutational epigenetic reprogramming, a hallmark in tumor biology.

10/08/2026

🔥🧰 Need to interrogate a complex inflammatory microenvironment? Enhance your IHC, IF, Flow, or WB experiments by combining markers for neutrophils and monocytes, M1/M2‑like macrophages, MDSCs, checkpoint ligands, and inflammasome components to build a clearer picture of the TME.

👉 Tap an expert‑curated shortlist of inflammatory pathways and cell markers to build your Tumor‑Promoting Inflammation research toolbox using the Hallmarks of Cancer .

Cancer cells hijack inflammatory mechanisms to promote their own growth and survival.

10/07/2026

A “pan” western blot-validated antibody might not give you the IHC coverage you need. Learn how our new Pan-Keratin MultiMab® Antibody mix, validated in both applications, enables confident ID of epithelial and tumor cells in your tissue samples.
https://hubs.ly/Q04zv0cg0

10/07/2026

Next week at ELRIG Drug Discovery 2026, explore CST solutions for spatial biology, immunoassays, and antibody conjugation—including SignalStar® Multiplex IHC, chimeric antibodies and validated antibody pairsbuilt for data you can trust.

10/05/2026

🏗️🩸Why is tumor vasculature chaotic, disorganized, and characteristically leaky?

👉 Explore the signaling events behind the “angiogenic switch” including markers from key pathways that are activated as part of tumor angiogenesis on the Hallmarks of Cancer .

Tumor angiogenesis fuels cancer growth by hijacking blood vessel formation. Learn how VEGF, HIF-1, and the signaling pathways drive this hallmark of cancer

09/30/2026

How the Inflammasome Drives Disease: Tackling Aberrant Inflammasome Signaling - Discover how aberrant inflammasome signaling drives chronic disease and explore CST-validated antibodies to study these non-communicable pathways.

Discover how aberrant inflammasome signaling drives chronic disease and explore CST-validated antibodies to study these non-communicable pathways.